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Abstract
Aquaglyceroporins (AQPs) transport water and glycerol and play important roles in drug-
uptake in pathogenic trypanosomatids. For example, AQP2 in the human-infectious African
trypanosome, Trypanosoma brucei gambiense, is responsible for melarsoprol and pentami-
dine-uptake, and melarsoprol treatment-failure has been found to be due to AQP2-defects
in these parasites. To further probe the roles of these transporters, we assembled a T. b.
brucei strain lacking all three AQP-genes. Triple-null aqp1-2-3 T. b. brucei displayed only a
very moderate growth defect in vitro, established infections in mice and recovered effec-
tively from hypotonic-shock. The aqp1-2-3 trypanosomes did, however, display glycerol
uptake and efflux defects. They failed to accumulate glycerol or to utilise glycerol as a car-
bon-source and displayed increased sensitivity to salicylhydroxamic acid (SHAM), octyl
gallate or propyl gallate; these inhibitors of trypanosome alternative oxidase (TAO) can
increase intracellular glycerol to toxic levels. Notably, disruption of AQP2 alone generated
cells with glycerol transport defects. Consistent with these findings, AQP2-defective, melar-
soprol-resistant clinical isolates were sensitive to the TAO inhibitors, SHAM, propyl gallate
and ascofuranone, relative to melarsoprol-sensitive reference strains. We conclude that
African trypanosome AQPs are dispensable for viability and osmoregulation but they make
important contributions to drug-uptake, glycerol-transport and respiratory-inhibitor sensitiv-
ity. We also discuss how the AQP-dependent inverse sensitivity to melarsoprol and respira-
tory inhibitors described here might be exploited.
Author summary
Protein channels in cell membranes transport specific molecules in and out of cells, and
can also facilitate drug-uptake. One such protein, known as an aquaglyceroporin (AQP),
allows parasitic African trypanosomes, the cause of lethal diseases in humans and live-
stock, to accumulate an arsenic-based drug known as melarsoprol. Unfortunately,
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parasites with a mutated AQP have resisted this drug and have spread, leading to treat-
ment-failure in>50% of patients in some areas. The functions of this particular AQP, and
two other similar AQPs normally expressed by these parasites, remain to be fully charac-
terised in trypanosomes. We therefore generated and characterised parasites lacking all
three AQPs. The cells grow well and, to our surprise, continue to effectively allow water to
flow in and out of the cell. Glycerol uptake and efflux are both perturbed, however. As a
consequence, drugs that cause these parasites to produce toxic quantities of glycerol are
more effective against parasites lacking the AQPs. Indeed, even the melarsoprol-resistant,
patient-derived parasites described above are more sensitive to these drugs. Our findings
not only reveal the relative contributions of the AQPs to glycerol transport, they also
point to therapies that could be more effective in the many patients infected by melarso-
prol-resistant parasites.
Introduction
African trypanosomes are parasitic protozoa and the causative agents of human and animal
African trypanosomiasis (HAT and AAT, respectively). These parasites are typically transmit-
ted by tsetse-flies, which are restricted to sub-Saharan Africa. HAT is typically fatal without
treatment, classified as a ‘neglected tropical disease’, and caused primarily by T. brucei gam-
biense (Western-Africa) but also by T. brucei rhodesiense (Eastern Africa). AAT is typically
caused by T. vivax, T. congolense or T. b. brucei, important veterinary and livestock pathogens;
T. b. brucei is a less-prevalent veterinary parasite and the favoured experimental sub-species.
Vaccine development is challenging and therapies suffer problems with toxicity, resistance,
cost, limited efficacy and difficulties with administration [1]. In addition, in the case of HAT,
diagnostic tools must define the stage of the disease if the appropriate therapy is to be selected
[1]. For treatment of the second stage for example, when parasites have entered the central
nervous system, the nifurtimox-eflornithine combination therapy is favoured [2]. The other
option is melarsoprol, but this is toxic [1]. Unfortunately, eflornithine is ineffective against
T. b. rhodesiense [3] so melarsoprol is currently the only option, despite its toxicity, against
advanced disease caused by this parasite.
Melarsoprol treatment-failure, in>50% of patients in some areas, has been reported for
both T. b. rhodesiense [4] and T. b. gambiense infections [5]. Melarsoprol-resistance can arise
due to reduced accumulation of drug, following aquaglyceroporin 2 (AQP2) mutation [6].
Both a trypanosome P2 adenosine transporter [7,8] and AQP2, an aquaglyceroporin with an
unusual arrangement of pore-lining residues comprising the ‘selectivity filter’ [9,10], contrib-
ute to melarsoprol-uptake; laboratory-engineered defects in these transporters render cells
melarsoprol-resistant. These cells also display cross-resistance to pentamidine [6], a drug used
to treat trypanosomiasis prior to central nervous system involvement. This may have little
impact in the clinic, however, because pentamidine remains effective at the high doses admin-
istered [11]. In terms of melarsoprol-resistance and treatment-failure, clinical isolates from
both the Democratic Republic of the Congo and South Sudan, dating back to the 1970s, display
AQP2-defects [12,13], and a clinical isolate was re-sensitised to both melarsoprol and pentami-
dine by the addition of an intact AQP2 gene [14]. A defect in a related Leishmania AQP has
been linked to widespread antimonial-resistant Leishmania infections in India [15].
There are three AQPs encoded in the T. b. brucei genome. AQP1 has been reported to local-
ise to the flagellar membrane in bloodstream-form cells [16], while plasma membrane localisa-
tion is indicated in insect-stage cells [17]. AQP3 displays a plasma membrane localisation in
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both bloodstream-form cells [9,16] and insect-stage cells [9]. AQP2, on the other hand, is
largely restricted to the flagellar pocket membrane in bloodstream-form cells, and then
becomes distributed more widely in the plasma membrane in insect-stage cells [9]. Heterolo-
gous expression of the T. b. brucei AQPs reveals their ability to transport water, mass: 18 Da;
ammonia, mass: 17 Da [18]; boric acid, mass: 62 Da [19]; glycerol, mass: 92 Da [20] and some
forms of trivalent arsenic, mass: 83–198 Da; and trivalent antimony, mass: 122–292 Da [21].
AQP2 gene-knockout in T. b. brucei reveals that this AQP can also specifically mediate uptake
of melarsoprol; mass: 398 Da, and pentamidine; mass: 340 Da [9,10]. These drugs have a sub-
stantially greater mass than other known AQP-substrates and recent evidence indicates that
pentamidine, rather than being a permeant, binds to and inhibits AQP2, suggesting that
uptake of this drug might require endocytosis [22].
To further probe AQP-function, we deleted all three T. b. brucei AQP genes from the T. b.
brucei genome. We found that trypanosomes tolerate the loss of all three AQPs. The triple
aqp1-2-3 null-strains, surprisingly, tolerated hypotonic shock, but were defective in glycerol
uptake, utilisation and efflux and, consequently, were sensitised to trypanosome alternative
oxidase (TAO) inhibitors that increase the intracellular glycerol concentration to toxic levels.
Notably, trypanosomes lacking only AQP2 were also defective in glycerol utilisation and efflux
and, as predicted by our T. b. brucei studies, clinical melarsoprol-resistant T. b. gambiense iso-
lates were also more sensitive to respiratory inhibitors relative to melarsoprol sensitive refer-
ence strains.
Results
T. b. brucei tolerates the loss of all three AQPs
T. b. brucei AQP1 (Tb927.6.1520) is on chromosome 6 and AQP2 (Tb927.10.14170) and AQP3
(Tb927.10.14160) are adjacent to each other on chromosome 10 (see Fig 1A). The AQP2-AQP3
locus is dispensable for growth [23]. AQP1 knockdown, using RNA interference was not asso-
ciated with any substantial growth-defect [16], but knockout of AQP1 has not, to our knowl-
edge, been attempted. T. b. brucei is diploid so we sequentially replaced the AQP1 alleles with
selectable markers (NPT and PAC) to determine whether AQP1 was dispensable (see Fig 1A).
We readily obtained aqp1-null strains, as confirmed by Southern blotting (Fig 1B).
We next devised a strategy to assemble triple aqp-null strains in a background that would
facilitate conditional expression of wild-type or mutant AQPs for complementation studies. In
order to recycle the limited number of selectable-markers available, we used a multi-step strat-
egy employing the meganuclease, I-SceI (see Materials and methods). Briefly, we set up strains
in the 2T1-background [24] in which meganuclease induction triggered the replacement of a
chromosomal knockout-cassette, bearing an I-SceI cleavage-site, with an allelic knockout-cas-
sette lacking an I-SceI cleavage-site. The cassette-integration and chromosomal allele-replace-
ment process was carried out for the AQP2-AQP3 locus and then repeated for the AQP1 locus,
such that the resulting strains bore a BLA-marker at both aqp2-aqp3 null alleles and an NPT-
marker at both aqp1 null alleles (Fig 1A). Southern blotting confirmed the absence of AQP1
(Fig 1B), AQP2 and AQP3 (Fig 1C) in the resulting aqp1-2-3 null strains. Thus, T. b. brucei tol-
erates the loss of all three AQPs.
The T. b. brucei AQPs have minimal impact on fitness or osmoregulation
We assessed fitness in cell-culture for the new aqp1 and aqp1-2-3 strains and compared these
to the wild-type and the previously described aqp2-3 strains [9]. The growth-curves indicated
a modest defect in the aqp1-2-3 strains and no apparent defect in the aqp1 or in the aqp2-3
strains (Fig 2A). The aqp1-2-3 strains were also able to establish infections in vivo in a mouse
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model; parasitaemia in all three mice was between 4 x 106 and 4 x 107 per ml of blood four
days after inoculation. These aqp1-2-3 strains also differentiated to the insect mid-gut stage
in vitro; equivalent to wild-type after one week in insect-stage growth-medium. Thus, we
observed only a modest fitness-defect in bloodstream-form cells in the absence of all three
AQPs but not in the absence of either AQP1 or AQP2-AQP3.
AQP2 specifically controls melarsoprol and pentamidine-uptake and has a particularly pro-
nounced impact on pentamidine-sensitivity in vitro [9]. Dose-response assays confirmed the
expected pentamidine-resistance in the aqp2-3 strains and indicated no additional resistance
in the aqp1-2-3 strains (Fig 2B); EC50-values were increased by approximately 30-fold relative
to wild-type in both cases. These results are consistent with the established specific role for
AQP2 in pentamidine (and melarsoprol) uptake and cross-resistance [9,12,23].
AQPs can transport water or small solutes. To explore the contribution of the T. b. brucei
AQPs to osmoregulation, we exposed cells to hypo-osmotic shock and monitored the
response. Under these conditions, cells swell rapidly and then, more slowly (10–20 min),
return to their original volume. We saw no, or only moderate, differences in the time taken
to recover for aqp1, aqp2-3 or aqp1-2-3 null-cells relative to wild-type trypanosomes (Fig 2C).
We conclude that the T. b. brucei AQPs have minimal impact on fitness or regulatory volume-
decrease after osmotic shock.
Glycerol uptake and utilisation are perturbed in aqp null T. b. brucei
We next assessed the ability of the aqp1-2-3 null T. b. brucei strains to use glycerol as a carbon-
source, which is possible in bloodstream form trypanosomes under aerobic conditions [25].
In preliminary experiments, aqp1-2-3 cells displayed sustained motility in 5 mM glucose and
Fig 1. T. b. brucei tolerates the loss of all three AQPs. (A) The schematic maps indicate the AQP1 and AQP2-3 regions replaced by selectable
markers as also indicated on the right. Δ indicates the regions deleted while the probes used for Southern blotting are shown above the maps. H, HpaI; S,
SacII. (B) The Southern blots indicate deletion of the AQP1 alleles in aqp1 and three independent aqp1-2-3 strains. Wild-type (WT) is shown for
comparison. Genomic DNA was digested with HpaI. (C) The Southern blots indicate deletion of the AQP2-3 alleles in aqp1-2-3 strains. WT is shown for
comparison. Genomic DNA was digested with SacII.
https://doi.org/10.1371/journal.ppat.1006307.g001
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fructose but these cells were immotile within 15-minutes in 5 mM glycerol. To quantify the
ATP-levels in cells incubated in 5 mM glucose or glycerol, we used a luminescence assay and
this confirmed that aqp1-2-3 cells were able to use glucose as a carbon-source but were unable
to utilise glycerol (Fig 3A). Since ATP-levels were significantly depleted (P<0.001) relative to
wild-type in aqp1-2-3 cells incubated in glycerol, we exploited this assay to assess the impact of
the various AQPs on glycerol utilisation; cells were harvested before they became immotile in
this assay so as to record quantitative differences among strains. As expected, ATP-levels were
not significantly diminished in any of the aqp-defective strains tested in glucose (Fig 3A). In
glycerol though, ATP-levels were significantly depleted (P<0.001) in aqp2, aqp2-3 and aqp1-2-
3 cells but not in aqp1 cells (Fig 3A). These results suggest that, among the AQPs, AQP2 makes
the greatest contribution to glycerol utilisation; this interpretation is supported by both effec-
tive utilisation of glycerol by aqp1 null cells and no increase in the glycerol-utilisation defect in
aqp2-3 cells relative to aqp2 cells.
Since glycerol utilisation does not directly reflect glycerol uptake, we next measured glyc-
erol uptake; in wild-type, triple-null and AQP2-complemented cells. The aqp1-2-3 cells
Fig 2. The T. b. brucei AQPs have minimal impact on fitness or osmoregulation. (A) Cumulative growth-curves for wild-type (WT), aqp1, aqp2-
3 and aqp1-2-3 null-strains. (B) Dose-response curves for pentamidine. (C) Hypo-osmotic shock assay. Open symbols, Earle’s salt buffer; filled
symbols, buffer diluted 50:50 with H2O. The recovery phase is shown. The phase-contrast images show two shocked and swollen cells (at left) and a
recovered cell (at right). Scale-bar, 5 μm. DNA was counter-stained with DAPI (blue).
https://doi.org/10.1371/journal.ppat.1006307.g002
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revealed almost complete ablation of glycerol-uptake (Fig 3B), consistent with minimal diffu-
sion of glycerol across the plasma membrane. AQP2 provided complementation of this defect,
albeit only partial (Fig 3B). Thus, AQP2 appears to make the greatest contribution to glycerol
utilisation but not the major contribution to glycerol uptake into the cell, possibly reflecting an
impact on transport into glycosomes, where glycerol is utilised [25].
T. b. brucei aqp-null cells display a glycerol efflux defect and respiratory
inhibitor-sensitivity
We next asked whether aqp-defective trypanosomes displayed glycerol-efflux defects as well as
the glycerol-uptake defects described above. Salicylhydroxamic acid (SHAM) increases intra-
cellular glycerol levels by inhibiting the trypanosome alternative oxidase (TAO) [26], a ubiqui-
nol oxygen oxidoreductase that is cyanide-insensitive and maintains redox balance as part of
the glycerol-3-phosphate oxidase system (see Fig 4A, left-hand panels). Consistent with a glyc-
erol-efflux defect, dose-response curves revealed that aqp1-2-3 null-cells were SHAM-sensitive
(EC50 decreased >7-fold) relative to wild-type cells (Fig 4A, right-hand panel: EC50 1.6 and
12 μM, respectively). SHAM plus glycerol rapidly kills bloodstream-form African trypano-
somes [27] (see Fig 4B, left-hand panel), but we predicted that the impact of added glycerol
would not be pronounced in glycerol-uptake defective aqp1-2-3 null-cells. Indeed, SHAM
dose-response curves generated in the presence of 10 mM glycerol (Fig 4B, right-hand panel)
revealed a substantial impact of glycerol against wild-type cells but only a very weak impact
against aqp1-2-3 null-cells; glycerol reduced SHAM EC50 values by 13 and 1.8-fold, respec-
tively; to 0.9 μM in both cases (compare Fig 4A and 4B). We also tested the additional TAO
inhibitors, propyl gallate and octyl gallate [28], against wild-type and aqp1-2-3 null-cells. Once
again, and consistent with a glycerol-efflux defect, dose-response curves revealed that aqp1-2-3
null-cells were TAO inhibitor sensitive relative to wild-type cells (Fig 4C); EC50 was reduced
by 4-fold and 5-fold, respectively.
Fig 3. Glycerol uptake and utilisation is perturbed in aqp-null T. b. brucei. (A) ATP levels were assessed in the strains indicated after incubation in 5
mM glucose or glycerol. Readings were taken in triplicate and normalised to substrate only. * indicates significantly different (P<0.001) to wild-type (WT)
using an ANOVA test in GraphPad Prism. Error bars, SD. (B) Radiolabelled glycerol uptake was assessed in the strains indicated. Readings were taken
in quadruplicate. * indicates significant difference (P<0.05) using a Student’s t-test. Error bars, SD.
https://doi.org/10.1371/journal.ppat.1006307.g003
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Fig 4. aqp-null T. b. brucei display defective glycerol-efflux and respiratory inhibitor-sensitivity. (A) Bloodstream T.
brucei express a SHAM-sensitive mitochondrial trypanosome alternative oxidase (TAO). Under aerobic conditions, TAO
activity allows ATP production without glycerol production as indicated by the black lines (left-hand blue ‘cell’). SHAM blocks
TAO-activity, leading to the anaerobic production of glycerol, which is toxic if not removed, as indicated by the black lines
(right-hand blue ‘cell’). SHAM dose-response curves for wild-type (WT) and aqp1-2-3 null-cells. EC50 values are indicated.
Drug-sensitivity in T. brucei aqp-nulls
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Since our glycerol-utilisation assays indicated a defect in aqp2 null T. b. brucei, we next
asked whether these cells also displayed increased sensitivity to SHAM, consistent with a
glycerol-efflux defect. We also tested SHAM-sensitivity in aqp2-3 null cells and in aqp1-2-3
null cells re-expressing AQP2; re-expressed AQP2 was localised to the flagellar pocket (Fig
4D, right-hand side), as expected [9]. The full set of SHAM (plus glycerol) EC50 values are
shown in Fig 4D. SHAM-sensitivity was indeed observed in aqp2 null (2.4-fold) aqp2-3 null
(3.2-fold) and aqp1-2-3 null cells (see above); these cells were all significantly more sensitive
to SHAM than wild type (Fig 4D), and AQP2 re-expression effectively reversed SHAM-sen-
sitivity in the aqp1-2-3 null background (Fig 4D). Also, 10 mM glycerol reduced SHAM EC50
values to <1 μM in all cell types and this reduction was significant in all but the aqp1-2-3 null
cells (Fig 4D), again consistent with almost complete ablation of glycerol transport in the lat-
ter case only.
Melarsoprol-resistant clinical isolates display respiratory inhibitor-
sensitivity
TAO inhibitor-sensitivity in aqp-null T. b. brucei may help to predict how trypanosomes in
patients will respond to respiratory inhibitors. In particular, naturally occurring melarsoprol-
resistant clinical T. b. gambiense isolates display chimerisation of the AQP2/3 genes [14].
Indeed, a substantial proportion, >50% in some areas, of circulating T. b. gambiense may be
AQP2-defective [12,13]; probably due to selection with melarsoprol since the 1940s. To analyse
whether this AQP2 defect might have an impact on respiratory inhibitor-sensitivity in clinical
isolates, we generated SHAM dose-response curves. The isolates selected were the melarso-
prol/pentamidine sensitive STIB930 and STIB891 strains (EC50 <10 and<2 nM, respectively,
according to [12]), the melarsoprol/pentamidine resistant K03048 and 40 AT isolates from
melarsoprol-relapsed patients (EC50 >20 and>50 nM, respectively, according to [12]) and a
40 AT-derivative that re-expresses AQP2 and is consequently restored to melarsoprol/pentam-
idine sensitivity [14]. The STIB930 and STIB891 strains are from patients in Coˆte d’Ivoire in
1978 [29] and Uganda in 1995 [30] and the K03048 and 40 AT isolates are from patients in
South Sudan in 2003 [31] and the Democratic Republic of the Congo in 2006 [13], respectively.
The STIB930 and STIB891 strains have intact AQP2 genes, while neither of the latter isolates
has an intact AQP2 gene [12].
As our studies on T. b. brucei had predicted, dose-response curves for the T. b. gambiense
strains revealed significantly lower EC50 values for both aqp2-defective strains relative to the
AQP2 controls (Fig 5A); the strains that lacked AQP2 were also confirmed to be pentamidine-
resistant (Fig 5A, inset), as previously reported [12]. These results suggest a glycerol-efflux
defect in the aqp2-defective clinical isolates. Re-expression of AQP2 in 40 AT cells did not sig-
nificantly alter SHAM-sensitivity, however (Fig 5A). This may indicate that the AQP2/3 chi-
mera interferes with glycerol efflux by recombinant AQP2, possibly due to the formation of
AQP hetero-tetramers that, despite the glycerol efflux defect, continue to contribute to pent-
amidine uptake by endocytosis [22]. The addition of 10 mM glycerol significantly reduced
SHAM EC50 values to<1 μM in all five cell-types (Fig 5A), indicating, as predicted, continued
(B) In the presence of SHAM and glycerol, the glycerol inhibits glycerol kinase (GK), also preventing ATP-production by the
anaerobic route (blue ‘cell’). SHAM dose-response curves as in A but in the presence of 10 mM glycerol. (C) Propyl gallate
and octyl gallate dose-response curves for wild-type (WT) and aqp1-2-3 null-cells. EC50 values are indicated. (D) SHAM
EC50 values +/- 10 mM glycerol from A-B and also from aqp2, aqp2-3 and aqp1-2-3 cells re-expressing GFPAQP2. *
indicates significantly different (P<0.01) to WT using an ANOVA test in GraphPad Prism. Pairwise comparisons +/- glycerol,
except in the case of the aqp1-2-3 null, indicated significant (P <0.001) differences using a Student’s t-test. Error bars, SD.
The images to the right show re-expression of GFPAQP2 in aqp1-2-3 null-cells.
https://doi.org/10.1371/journal.ppat.1006307.g004
Drug-sensitivity in T. brucei aqp-nulls
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006307 March 30, 2017 8 / 16
glycerol influx in each case. To extend these findings, we examined the impact of two addi-
tional TAO inhibitors, propyl gallate and ascofuranone [32], on the same set of strains
described above. Dose-responses for propyl gallate (Fig 5B) and ascofuranone (Fig 5C)
revealed similar EC50 profiles as detailed above for SHAM. Although the STIB891 EC50 for
propyl gallate was relatively low, both aqp2-defective strains displayed an even lower EC50, and
both were significantly more sensitive to the respiratory inhibitors than the STIB930 control
(Fig 5B and 5C). Once again, re-expression of AQP2 in 40 AT cells did not significantly alter
respiratory inhibitor sensitivity (Fig 5B and 5C).
Together, our results indicate that triple aqp-null and aqp2 null T. b. brucei exhibit defects
in bidirectional glycerol flux. The evidence is three-fold; first, failure to take up or effectively
utilise glycerol as a carbon source; second, sensitivity to multiple respiratory inhibitors which
produce toxic levels of intracellular glycerol; and third, no significant increase in SHAM-
Fig 5. Respiratory inhibitor-sensitivity in T. b. gambiense isolates and AQP-mediated glycerol transport. (A) SHAM EC50 values for the T. b
gambiense strains are indicated +/- glycerol. The inset shows pentamidine EC50 values. * indicates significantly different (P<0.05) to STIB930 using an
ANOVA test in GraphPad Prism. All pairwise comparisons +/- 10 mM glycerol also indicated significant (P <0.001) differences using a Student’s t-test.
Error bars, SD. (B) Propyl gallate and (C) Ascofuranone EC50 values. Other details as in A. (D) Model for glycerol transport by AQPs in T. b. gambiense.
The weight of the arrows indicates relative impact on glycerol utilisation and efflux, with AQP2 being the major contributor; note that transport across both
the plasma and glycosomal membranes contributes to glycerol utilisation and efflux, see the text for more details. The right-hand panel indicates the
situation in melarsoprol-resistant (reduced melarsoprol uptake) and SHAM-sensitive (reduced glycerol efflux) clinical isolates where a chimeric AQP2/3
replaces AQP2 and AQP3.
https://doi.org/10.1371/journal.ppat.1006307.g005
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sensitivity in excess glycerol in triple-null cells. Thus, glycerol flux appears to be almost absent
in aqp1-2-3 triple-null cells. Our results also indicate that AQP2 makes a key contribution to
glycerol utilisation and efflux. This interpretation is supported by a substantial defect in glyc-
erol utilisation and sensitivity to SHAM in aqp2 null-cells; a phenotype that is reversed by
AQP2 re-expression in aqp1-2-3 triple-null cells. Importantly, analysis of melarsoprol/pentam-
idine sensitive T. b. gambiense reference strains and melarsoprol/pentamidine resistant clini-
cal-isolates supports the idea that AQP2 also makes a key contribution to glycerol efflux in
trypanosomes in patients (see Fig 5D). We propose that it is the replacement of AQP2 with the
AQP2-3 chimera in clinical isolates (Fig 5D) that increases sensitivity to respiratory inhibitors.
Notably, although the chimera comprises <15% of the AQP3-sequence at the C-terminus, like
AQP3 [9], the chimera is distributed within the plasma membrane [10]; AQP2 by contrast is
concentrated in the flagellar pocket in bloodstream-form cells [9].
Discussion
Here, we describe bloodstream-form T. b. brucei strains that lack all three AQPs. These strains
exhibit only a minimal fitness-defect and no apparent osmoregulation-defect. They do, how-
ever, exhibit bidirectional defects in glycerol transport. AQP2 is an important determinant of
cross-resistance to melarsoprol and pentamidine and this AQP was also found to make a key
contribution to glycerol transport. Finally, following analysis of clinical isolates, we propose
that the AQPs behave similarly in parasites in patients, suggesting that TAO-inhibitors may be
more effective against melarsoprol-resistant African trypanosome infections.
The triple aqp-null strain was assembled with the primary purpose of dissecting AQP-func-
tions. We note though that successful generation of such a strain indicates that the AQPs are
unlikely to be suitable therapeutic targets for inhibition. It was also possible to generate malaria
parasites that lacked the single encoded AQP gene; these aqp-null Plasmodium parasites dis-
played defective glycerol uptake and moderately reduced virulence [33]. We find that aqp1-2-3
null T. b. brucei establish parasitemia in mice. Indeed, strains isolated from patients following
melarsoprol treatment-failure, in an area where treatment-failure is common, display fusion
of AQP2 and AQP3 to form an AQP2/3 chimera [12,13]. This suggests, either that these AQPs
are dispensable at all stages of the life-cycle, or that the chimera complements the defect(s). It
remains possible that AQP1 or the AQP2/3 chimera have essential functions in other life-cycle
stages, but we were able to differentiate triple-null cells to the procyclic stage in vitro and also
note that T. vivax and T. congolense appear to lack both the AQP1 and AQP2 genes [34].
The three T. b. brucei AQPs were previously reported to play a role in osmoregulation [16].
The same study indicated an additional glycerol transport activity in T. b. brucei [16]. In con-
trast, we observe minimal or no defect in osmoregulation and detected minimal residual glyc-
erol flux in triple aqp-null cells. The former difference could potentially reflect adaptation in
null cells but the latter difference is likely explained by only 36% AQP2 knockdown or 73% tri-
ple AQP knockdown in the former study [16]. Notably, adaptation, if it operates, would also
be expected in clinical and veterinary isolates that lack AQP genes. How is osmoregulation
achieved in other parasitic trypanosomatids? A contractile vacuole/spongiome complex is
present in Trypanosoma cruzi and Leishmania major, and aqua(glycero)porins have been local-
ised to these organelles [35,36]; the T. cruzi aquaporin is not closely related to the T. brucei
AQPs but Leishmania AQP1 is closely related [6] and does play a role is osmoregulation [37].
However, water can diffuse across membranes and alternative mechanisms of osmoregulation
do operate. In both L. major [38] and Crithidia luciliae [39], cells tolerate hypotonic stress
through the efflux of amino acids and, in Leishmania donovani, also through the efflux of inor-
ganic osmolytes [40]. Thus, T. brucei AQPs may contribute to osmoregulation, but we suggest
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that the primary roles of these AQPs in bloodstream-form cells are the transport of glycerol
and other solutes.
Under aerobic conditions, T. b. brucei can use glycerol as a carbon source [41]. We found
that triple aqp-null cells, and even aqp2-null cells, fail to effectively utilise glycerol. This indi-
cates that AQPs contribute to glycerol-uptake and utilisation and that AQP2 makes a key con-
tribution. Since glycerol utilisation and production under anaerobic conditions occurs inside
glycosomes [25], we must consider glycosomal transport as well as transport across the plasma
membrane. A T. cruzi aquaporin is localised to acidocalcisomes [36] but AQPs have not been
reported to be associated with glycosomes. It is possible that the T. brucei AQPs are also pres-
ent in glycosomal membranes but there may equally be alternative glycerol transporters associ-
ated with these organelles.
Carbohydrate catabolism in African trypanosomes has been considered a promising poten-
tial antitrypanosomal therapeutic target for>40 years. Indeed, a SHAM plus glycerol combi-
nation blocks aerobic and anaerobic glycolysis in vivo and clears parasites from the blood of
experimental animals within 5 min [27]. Since this combination is so effective, glycerol-efflux
has remained of particular interest [26]. SHAM inhibits TAO, which is upregulated in the
bloodstream-form and not found in other trypanosomatids or in the mammalian host [26].
TAO inhibition blocks the aerobic pathway and increases the production of ATP via the
reverse-action of glycerol kinase [41]. The glycerol produced by this anaerobic glycolysis will
become toxic if not removed from the cell. If glycerol is not removed, it reverses the action of
glycerol kinase by mass-action and also blocks the anaerobic pathway, explaining the toxic
effect of SHAM plus glycerol. Our findings indicate that this SHAM-glycerol effect is depen-
dent upon the AQPs. Indeed, our results show that aqp2, aqp2-3 and aqp1-2-3 cells, and clini-
cal isolates lacking AQP2 but with an AQP2/3 chimera, display increased sensitivity to multiple
respiratory inhibitors in the absence of exogenous glycerol. Thus, AQP2 plays a key role in
both glycerol utilisation and efflux.
The combination of SHAM with a large dose of glycerol, required at up to 15 g per kg,
remains impractical as a therapy [42]. More potent antitrypanosomal TAO inhibitors have
been developed, however [42,43,44]. Our finding, therefore, that aqp2-deficiency is associated
with TAO-inhibitor sensitivity, has implications for potential future therapeutic strategies. For
example, new TAO-inhibitors may be effective as mono-therapies against melarsoprol-resis-
tant T. b. rhodesiense [4], or T. b. gambiense, known to lack AQP2 in the latter case [12]. This
may also be the case for T. vivax and T. congolense, where the reference genomes indicate
the absence of both the AQP1 and AQP2 genes and the presence of only an AQP3-like gene
(Tvy486_1013610 and TcIL3000_10_12040, respectively) [34]. Indeed, although SHAM alone
is ineffective against T. vivax [45], ascofuranone is effective against T. vivax infections in mice
without added glycerol [32]. This and other TAO inhibitors are thought to function by mim-
icking ubiquinol and blocking electron transfer to the oxidase [46].
Melarsoprol has been highly effective against trypanosomiasis but clinical resistance, due to
an aqp2-defect, has become widespread [12]. An option, therefore, could be to apply TAO-
inhibitors and melarsoprol sequentially or in combination; this could establish a counter-resis-
tance approach whereby AQP2 is required for both the uptake and efflux of toxins. Further sim-
ilar options may emerge from on-going efforts to develop safer and orally available arsenical
formulations [47]. Ultimately, reciprocal shifts in drug-sensitivity, such as the example we
describe here, may be exploited to develop novel paradigms of targeted-therapy. Such strategies
could restrict or even reverse the emergence and spread of drug resistance in human and live-
stock parasites, which would be of great value given the high cost of developing new therapies.
Our studies on aqp-null T. b. brucei and on clinical isolates of T. b. gambiense have revealed
bidirectional defects in glycerol transport and the key contribution of AQP2, the AQP
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specifically responsible for melarsoprol- and pentamidine-sensitivity, now also shown to
impact respiratory inhibitor sensitivity. Thus, AQPs impact the efficacy of three major classes
of antitrypanosomal drugs. These new mechanistic insights into differential sensitivities to
antitrypanosomal drugs, in both clinical and veterinary settings, are potentially exploitable.
Materials and methods
T. b. brucei growth and manipulation
Bloodstream-form T. brucei, Lister 427, MiTat 1.2, clone 221a, and all derivatives were cultured
in HMI-11 as previously described [48]. Bloodstream-form T. b. gambiense were cultured in
the same media but with 15% FCS and 5% human serum. 2T1 [24], aqp2 [9], aqp2-3 [23],
STIB930, STIB891, K03048, 40 AT [12] and 40 AT plus AQP2 [14] strains were described pre-
viously. SHAM, glycerol, octyl gallate and propyl gallate were from Sigma. SHAM was dis-
solved in DMSO, the gallates were dissolved in 70% ethanol or DMSO and ascofuranone was
dissolved in DMSO. EC50 assays were performed using the AlamarBlue method as described
[49] with 10 mM glycerol added as appropriate; drug exposure was for 66–67 h and Alamar-
Blue incubation was for 5–6 h. Plates were read on an Infinite 200 Pro plate-reader (Tecan).
Growth rates in culture were monitored by splitting to 1 x 105 cells/ml and by counting daily.
Three Balb/c mice were infected with aqp1-2-3 triple-null trypanosomes by intraperitoneal
injection of 104 cells in 0.2 ml of growth medium. Parasitaemia was determined daily following
tail bleeds. Mice were purchased from Envigo, UK. Differentiation to insect-stage, procyclic
form cells was initiated by washing 2 x 107 cells twice in DTM [50] and re-suspending in 5 ml
DTM supplemented with citrate (3 mM) and cis-aconitate (3 mM) at 27˚C.
Plasmids and strain construction
For AQP-knockout plasmid constructs, AQP-flanking sequences were inserted on both sides of
selectable marker cassettes. Restriction enzyme cleavage at the distal ends of the AQP targeting
regions was used to linearise plasmid constructs prior to transfection. The AQP2-3 locus was
disrupted by replacing a 4,772 bp fragment [9] with BLA and a modified NPT selectable marker
cassette. The AQP1 locus was disrupted by replacing a 647 bp fragment with NPT and (a modi-
fied) PAC selectable marker cassettes. The AQP1:PAC and AQP2-3:NPT cassettes were modified
using annealed oligonucleotides (XSceF: CTAGTAGGGATAACAGGGTAAT, and XSceR:
CTAGGATTACCCTGTTATCCCTA) to engineer an I-SceI site at an Xbal site adjacent to each
5’-targeting region. Other oligonucleotide sequences are available upon request.
During creation of the aqp1-2-3 triple-null strains, selectable markers were recovered
using I-SceI meganuclease-induction in a 2T1 (BLE:PAC) background [48]. Briefly, a pRPaSce
[51] construct (HYG recovers PAC) was introduced at the tagged locus on chromosome 2
and the AQP2-3 alleles were replaced with BLA and NPT-cassettes, the latter containing the
flanking I-SceI cleavage site. Induction with 1 μg.ml-1 tetracycline triggered I-SceI cleavage
and duplication of the BLA-cassette (NPT recovered). A similar process was repeated for
AQP1 alleles but this time with NPT and PAC-cassettes (PAC recovered). The ph3E construct
[48] was then used to remove the I-SceI cassette (PAC recovered HYG). A pRPaAQP2 con-
struct (HYG recovers PAC) was then used for expression of recombinant AQP2 in the 2T1-
aqp1-2-3 null-background (BLE:BLA:NEO:PAC). Selectable-marker recovery was confirmed
by screening individual clones in multi-well plates. Strains were transfected using a Nucleo-
fector (Lonza) and cytomix. Transformants were selected with phleomycin (1 μg.ml-1), blas-
ticidin (10 μg.ml-1), G418 (2 μg.ml-1), puromycin (2 μg.ml-1) and hygromycin (2.5 μg.ml-1)
as appropriate and AQP knockout was confirmed by Southern blotting, carried out accord-
ing to standard protocols.
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Hypo-osmotic shock assays
Cell volume during hypo-osmotic shock was assessed using a light-scattering assay. Briefly, 5 x
107 cells were pelleted and resuspended in ice cold Earle’s salt buffer (116 mM NaCl, 1.8 mM
CaCl2, 5mM KCl, 0.8 mM MgSO4, 1 mM NaH2PO4, 30 mM HEPES, 30 mM glucose, pH 7.4).
1.3 x104 cells in 100 μl per well were added to 96-well plates. Either 100 μl of cold deionised
water (hypo-osmotic) or Earle’s salt buffer (iso-osmotic) was added to each well. Results were
then immediately read at 18-s intervals over a course of 25-min, using a Tecan Infinite 200 pro
plate-reader at 595 nM absorbance.
Microscopy
For phase and fluorescence microscopy, cells were fixed in 1% paraformaldehyde, settled onto
slides and mounted in Vectashield (Vector Laboratories) containing 4,6-diamidino-2-pheny-
lindole (DAPI). Images were captured using an Axiovert 200 epifluorescence microscope in
conjunction with an Axiocam 105 colour camera (Zeiss) and were processed using Zen digital
imaging suite.
ATP quantification
We used the CellTiter-Glo luminescence assay (Promega). Briefly 5 x 106 cells were washed
twice with cold PBS and re-suspended in 1 ml of 37˚C PBS with either 5 mM glucose or glyc-
erol in PBS for 20-min before performing the assay as per the manufacturers’ instructions.
Plates were read on an Infinite 200 Pro plate-reader (Tecan). Values were compared to an ATP
standard-curve.
Glycerol uptake assay
We used a [14C] glycerol centrifugation method [52] with minor modifications. Briefly, cells
were pelleted by centrifugation (1,000 g, 10 min), washed twice in transport buffer (33 mM
HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 CaCl2, 0.07 MgSO4, 5.8 mM Na2PO4, 0.3 mM
NaHCO3, 14 mM glucose, pH 7.3) and diluted to 1 x 10
8/ml in transport buffer on ice. Uptake
was measured (at 37˚C) by introducing 100 μl of cells to 100 μl transport buffer, containing
0.25 uCi glycerol. This reaction mixture was immediately loaded onto 100 μl of dibutyl phthal-
ate (Sigma) in 1.5 ml Eppendorf tubes. After incubation for 5 min, cells were pelleted through
the oil layer by centrifugation (16,000g, 1 min). The tubes were then frozen on liquid nitrogen
and the bottoms of the tubes, containing pellets, were snipped directly into scintillation vials.
Pellets were solubilised overnight in 150 μl 1 M NaOH, before mixing with 2 ml of scintillation
fluid and reading on a scintillation counter (Beckman LS 6500) for 1 min.
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